$CUE News
Last published 1mo ago
- 1mo agoCUECue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous UrticariaGlobeNewswirePrimary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profileClinically different efficacy profile observed relative to XOLAIR®
- 2mo agoCUECue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireAnnounced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applicationsCompleted a $50 million private placement (PIPE) to further fund clinical development and the portfolio with
- 3mo agoCUECue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug SubmissionGlobeNewswireBOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment
- 4mo agoCUECue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & DevelopmentGlobeNewswireBOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment
- 5mo agoCUECue Biopharma Announces Board Transition and Addition of New Directors with Continued Company EvolutionGlobeNewswireDaniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance and executive
- 5mo agoCUECue Biopharma to Present at the 2026 Jefferies Global Healthcare ConferenceGlobeNewswireBOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunological disorders,
- 6mo agoCUECue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic DevelopmentsGlobeNewswireEnhanced the company's portfolio with an exclusive license for, CUE-221, a Phase 2 program targeting allergic disease Hosted virtual R&D day showcasing CUE-401, a bifunctional IL-2 and TGF-B program targeting
- 6mo agoCUECue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed
- 6mo agoCUECue Biopharma Announces $30 Million Private PlacementGlobeNewswireBOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 6mo agoCUECue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE AntibodyGlobeNewswireNovel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue Biopharma plans to initiate global Phase 2b trial in food allergy following anticipated
- 6mo agoCUECue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage CompanyGlobeNewswireBOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 6mo agoCUECue Biopharma Announces 1-for-30 Reverse Stock SplitGlobeNewswireBOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 7mo agoCUECue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026GlobeNewswireBOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 7mo agoCUECue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License AgreementGlobeNewswirePreclinical milestone for selection and approval of first compound for lead optimization has been achievedFurther development validates the potential intended mechanistic effect of CUE-501 for T cell-mediated targeted
- 7mo agoCUECue Biopharma Announces CEO TransitionGlobeNewswireBOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 7mo agoCUECue Biopharma to Host Virtual R&D Day Event on April 7, 2026GlobeNewswireVirtual Event will feature Key Opinion Leaders (KOLs) Richard DiPaolo, PhD, and Jonathan Kay, MD, FACP, MACR Cue Biopharma management and KOLs will discuss CUE-401, the company's lead asset for the treatment of
- 8mo agoCUECue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsGlobeNewswireAdvanced research and development of CUE-401 for IND (Investigational New Drug) readiness –CUE-401 is the Company's lead asset for the treatment of autoimmune and inflammatory diseasesAppointed industry veteran Lucinda
- 8mo agoCUECue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026GlobeNewswireBOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 8mo agoCUECue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory DiseasesGlobeNewswireIn two non-GLP studies, CUE-401 was well tolerated with no adverse events observed Proof-of-concept studies reinforce promising preclinical profile and therapeutic potential of CUE-401 BOSTON, Mass., Feb. 17, 2026
- 9mo agoCUECue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business OfficerGlobeNewswireBOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 10mo agoCUECue Biopharma Announces Pricing of $10 Million Public OfferingGlobeNewswireBOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 10mo agoCUECue Biopharma Announces Proposed Public OfferingGlobeNewswireBOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 12mo agoCUESingapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB AppointmentsBusiness Wire"Seed-and-Boost" Approach with Breakthrough Potential, Poised to Transform the Cancer Immunotherapy Landscape ImmunoScape Pte. Ltd., an A*STAR spin out backed by Amgen Ventures and EDBi that is developing
- 12mo agoCUECue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswireAnnounced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Company is entitled to receive upfront payments totaling $15M Announced strategic
- 1y agoCUECue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid TumorsGlobeNewswireExclusive collaboration and license agreement focuses on advancing novel T cell therapy "Seed-and-Boost" approach exploiting the mechanism of the CUE-100 series of Immuno-STATs®Novel therapeutic approach is designed
- 1y agoCUECue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic CandidatesGlobeNewswireUsman Azam, M.D., is appointed President and Chief Executive Officer of Cue Biopharma, effective September 29, 2025Daniel Passeri, Chief Executive Officer of Cue Biopharma, transitions to Strategic Advisor to provide ongoing support to the Company C
- 1y agoCUECue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare ConferenceGlobeNewswireBOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 1y agoCUECue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma MultiformeGlobeNewswireFirst patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage
- 1y agoCUECue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswireReceived FDA feedback on Pre-IND Briefing Document reinforcing Company's intention to advance investigational new drug (IND) submission for CUE-401 to address unmet need in the treatment of autoimmune disease.
- 1y agoONCYCUEVSTMALLO+1High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy HeadwindsPR NewswireUSA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts to U.S. research budgets ...
- 1y agoCUECue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck CancerGlobeNewswireAdditional complete response (CR) observed in patient with multiple tumorsConfirmed overall response rate (ORR) of 50% in patients with combined positive score (CPS) ≥1, including 50% ORR in patients with low CPS
- 1y agoCUECue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic MalignanciesGlobeNewswireORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC12-month landmark survival of 88% and mOS of 32 months BOSTON, July 01, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage
- 1y agoCUECue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune DiseaseGlobeNewswireBOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 1y agoCUECue Biopharma Reports First Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswireAnnounced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments Raised gross proceeds of ~$20
- 1y agoCUECue Biopharma to Host Virtual Investor Event on May 15, 2025GlobeNewswireMobilizing the Immune System: Cue Biopharma's Novel Biologics Portfolio Event Virtual Event will Feature Key Opinion Leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD BOSTON, May 08, 2025 (GLOBE
- 1y agoCUECue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences ConferenceGlobeNewswireBOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 1y agoCUECue Biopharma Announces Pricing of Approximately $20 Million Public OfferingGlobeNewswireBOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 1y agoCUECue Biopharma Announces Proposed Public OfferingGlobeNewswireBOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 1y agoCUECue Biopharma to Host Business Update Call and WebcastGlobeNewswireBOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 1y agoCUEBoehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseasesGlobeNewswirePartnership bolsters Boehringer's autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need.The agreement focuses on further research and development of a novel,
- 1y agoCUECue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsGlobeNewswireBOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- - Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 1y agoCUECue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 1y agoCUECue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswireBOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 1y agoCUECue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswireBOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 1y agoCUECue Biopharma Announces Strategic Organizational TransitionGlobeNewswireDaniel Baker, M.D., will join Cue Biopharma's executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish Suri, Ph.D., president & chief scientific officer (CSO) of Cue
- 1y agoCUECue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare ConferenceGlobeNewswireBOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 2y agoCUECue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual MeetingGlobeNewswireObjective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival (mOS) of 21.8 months in first line (1L) HPV+ R/M HNSCC patients treated with CUE-101 and
- 2y agoCUECue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual MeetingGlobeNewswireBOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 2y agoCUECue Biopharma Announces Pricing of $12.0 Million Public OfferingGlobeNewswireBOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
- 2y agoCUECue Biopharma Announces Proposed Public OfferingGlobeNewswireBOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate